Cyclacel Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting

Cyclacel Announces Multiple Abstracts Selected for Presentation at American
Association for Cancer Research Annual Meeting

BERKELEY HEIGHTS, N.J., April 3, 2013 (GLOBE NEWSWIRE) -- Cyclacel
Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company),
a biopharmaceutical company developing oral therapies that target the various
phases of cell cycle control for the treatment of cancer and other serious
disorders, announced that two abstracts highlighting clinical and preclinical
data for Cyclacel's cell cycle inhibitor drugs have been selected for an oral
presentation during a Clinical Trials symposium and a poster presentation at
the American Association for Cancer Research (AACR) annual meeting, being held
April 6-10, 2013, at the Walter E. Washington Convention Center in Washington,
DC.

Details for the presentations are as follows:

Abstract:       LB-202
Title:         Responses to sequential sapacitabine and seliciclib in
                patients with BRCA-deficient solid tumors
Date/Time:     Tuesday, Apr 09, 2013, 2:00 PM - 2:20 PM
Location:      Room 146
Session Title: Clinical Pharmacology of Novel Agents in Solid Tumors
                (Clinical Trials Symposium)
                Geoffrey I. Shapiro, John Hilton, James M. Cleary, Sara M.
                Tolaney, Leena Ghandi, Eunice L. Kwak, Jeffrey W. Clark,
                Andrew Wolanski, Tracy Bell, John Schulz, Sheelagh Frame,
Authors:        Chiara Saladino, Morag Hogben, Scott J. Rodig, Judy H. Chiao,
               David Blake. Dana-Farber Cancer Institute, Boston, MA,
                Massachusetts General Hospital, Boston, MA, Cyclacel Ltd,
                Dundee, United Kingdom, Brigham and Women's Hospital, Boston,
                MA.
               
Abstract:      3418
Title:         Mechanism of cell death induced by the DNA strand-breaking
                nucleoside analogue CNDAC
Date/Time:     Tuesday, Apr 09, 2013, 8:00 AM - 12:00 PM
               Hall A-C, Poster Section 43, Poster Board Number: 13
Session Title: Targeting Cell Cycle and DNA Damage
Authors:       Xiaojun Liu, Billie Nowak, Yingjun Jiang, Walter Hittelman,
                William Plunkett. UT MD Anderson Cancer Center, Houston, TX.

The abstracts can be accessed through the AACR website, www.aacr.org. Please
note that according to AACR policy, all data are embargoed until the time of
the beginning of the presentation.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target
the various phases of cell cycle control for the treatment of cancer and other
serious diseases. The Company's most advanced oral product candidate,
sapacitabine, is the subject of SEAMLESS, a Phase 3 trial being conducted
under an SPA with the FDA as front-line treatment of acute myeloid leukemia
(AML) in the elderly and Phase 2 studies for AML, myelodysplastic syndromes
(MDS), chronic lymphocytic leukemia (CLL) and solid tumors including breast,
lung, ovarian and pancreatic cancer. Cyclacel's pipeline includes seliciclib,
a CDK inhibitor, in Phase 2 for lung and nasopharyngeal cancer and in Phase 1
in combination with sapacitabine; and CYC065, a second generation CDK
inhibitor, in IND-directed development. Cyclacel's strategy is to build a
diversified biopharmaceutical business focused in hematology and oncology
based on a development pipeline of novel drug candidates. Please visit
www.cyclacel.com for additional information.

Forward-looking Statements

This news release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy, safety and
intended utilization of Cyclacel's product candidates, the conduct and results
of future clinical trials, plans regarding regulatory filings, future research
and clinical trials and plans regarding partnering activities. Factors that
may cause actual results to differ materially include the risk that product
candidates that appeared promising in early research and clinical trials do
not demonstrate safety and/or efficacy in larger-scale or later clinical
trials, trials may have difficulty enrolling, Cyclacel may not obtain approval
to market its product candidates, the risks associated with reliance on
outside financing to meet capital requirements, and the risks associated with
reliance on collaborative partners for further clinical trials, development
and commercialization of product candidates. You are urged to consider
statements that include the words "may," "will," "would," "could," "should,"
"believes," "estimates," "projects," "potential," "expects," "plans,"
"anticipates," "intends," "continues," "forecast," "designed," "goal," or the
negative of those words or other comparable words to be uncertain and
forward-looking. For a further list and description of the risks and
uncertainties the Company faces, please refer to our most recent Annual Report
on Form 10-K and other periodic and other filings we file with the Securities
and Exchange Commission and are available at www.sec.gov.Such forward-looking
statements are current only as of the date they are made, and we assume no
obligation to update any forward-looking statements, whether as a result of
new information, future events or otherwise.

© Copyright 2013 Cyclacel Pharmaceuticals, Inc.All Rights Reserved.The
Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.

CONTACT: Contact for Cyclacel Pharmaceuticals, Inc.

         Investors/Media: Corey Sohmer,
         (908) 517-7330, csohmer@cyclacel.com

Cyclacel Pharmaceuticals logo
 
Press spacebar to pause and continue. Press esc to stop.